DUBLIN, Calif.--(BUSINESS WIRE)--SuperGen, Inc. (NASDAQ:SUPG) a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Gregory Berk, M.D., Chief Medical Officer, has left the Company. Michael D. Young, M.D., Ph.D., a current member of the SuperGen board of directors and Chairman and Chief Scientific Officer of Strategic Healthcare Development, LLC, will serve as SuperGen’s interim Chief Medical Advisor, consulting to James S. J. Manuso, Ph.D., President and Chief Executive Officer. Dr. Manuso will oversee both clinical and regulatory development until a replacement for Dr. Berk can be found. A global search for a new chief medical officer has been initiated.
